

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2022/140618 A8**

(43) International Publication Date  
30 June 2022 (30.06.2022)

WIPO | PCT

- (51) **International Patent Classification:**  
*A61K 48/00* (2006.01) *C12N 15/861* (2006.01)
- (21) **International Application Number:**  
PCT/US2021/064979
- (22) **International Filing Date:**  
22 December 2021 (22.12.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
63/129,233 22 December 2020 (22.12.2020) US
- (71) **Applicant:** ENSOMA, INC. [US/US]; 451 D Street, Suite 600, Boston, Massachusetts 02210 (US).
- (72) **Inventors:** ROY, Soumitra; c/o Ensoma, Inc., 451 D Street, Suite 600, Boston, Massachusetts 02210 (US).  
BASHYAM, Ashvin Reddy; c/o Ensoma, Inc., 451 D Street, Suite 600, Boston, Massachusetts 02210 (US).
- (74) **Agent:** SHORE, David E. et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

**Published:**

- with international search report (Art. 21(3))  
— with sequence listing part of description (Rule 5.2(a))

**(48) Date of publication of this corrected version:**

20 October 2022 (20.10.2022)

**(15) Information about Correction:**

see Notice of 20 October 2022 (20.10.2022)

**Previous Correction:**

see Notice of 04 August 2022 (04.08.2022)

**(54) Title:** ADENOVIRAL GENE THERAPY VECTORS




Fig. 1

(57) **Abstract:** The present disclosure includes adenoviral vectors characterized by efficient transduction of HSCs, e.g., for *in vivo* gene therapy. The present disclosure includes, among other things, Ad3, Ad7, Ad11, Ad14, Ad16, Ad21, Ad34, Ad37, and Ad50 vectors and genomes. Ad3, Ad7, Ad11, Ad14, Ad16, Ad21, Ad34, Ad37, and Ad50 vectors and genomes of the present disclosure can include therapeutic payloads.